Short answer · Medically reviewed summary · Last updated: 2026-05-08
Recent advances in Rickets, particularly in the management of X-linked hypophosphatemia (XLH), have shifted toward targeted biological therapies like burosumab, which directly address the underlying hormonal dysregulation. While traditional nutritional Rickets is largely preventable through vitamin D and calcium supplementation, ongoing research is now focused on precision medicine, gene therapy, and novel biomarkers for rare hereditary forms of the disease. What are the most promising research directions for Rickets? Modern research into Rickets is moving beyond basic supplementation toward identifying the genetic pathways that govern phosphate homeostasis.
What are the latest advances in Rickets?
Latest advances in Rickets: recent research, treatments in development and what they could mean, with sources.
Recent advances in Rickets, particularly in the management of X-linked hypophosphatemia (XLH), have shifted toward targeted biological therapies like burosumab, which directly address the underlying hormonal dysregulation. While traditional nutritional Rickets is largely preventable through vitamin D and calcium supplementation, ongoing research is now focused on precision medicine, gene therapy, and novel biomarkers for rare hereditary forms of the disease.
What are the most promising research directions for Rickets?
Modern research into Rickets is moving beyond basic supplementation toward identifying the genetic pathways that govern phosphate homeostasis. Scientists are investigating the role of Fibroblast Growth Factor 23 (FGF23) in various forms of hypophosphatemic Rickets. By neutralizing the overactive FGF23 pathway, researchers are successfully developing treatments that improve bone mineralization and growth velocity in children with refractory forms of the condition.
What are the recent breakthroughs in treating Rickets?
The most significant recent breakthrough has been the clinical adoption of anti-FGF23 monoclonal antibodies. Unlike traditional therapy—which requires multiple daily doses of oral phosphate and active vitamin D—these biologics offer a more targeted approach. Key developments include:
- Biological therapy: Burosumab (Crysvita) has become the standard of care for XLH, significantly reducing the severity of Rickets-related skeletal deformities.
- Biomarker development: New assays for serum intact FGF23 are helping clinicians distinguish between different genetic types of hypophosphatemia more rapidly.
- Genetic screening: Expanded genomic panels now allow for earlier diagnosis of rare, non-nutritional Rickets, enabling intervention before irreversible bone damage occurs.
How can patients participate in clinical trials?
Research into Rickets is highly active, with numerous studies listed on ClinicalTrials.gov. Patients and caregivers can search by condition to find trials evaluating new drug delivery systems or long-term outcomes of existing biologics. It is essential to discuss these opportunities with a metabolic bone specialist or pediatric endocrinologist who can navigate the inclusion criteria and potential risks of experimental protocols.
Next steps
- Consult a pediatric endocrinologist or metabolic bone specialist to discuss the latest management protocols.
- Visit ClinicalTrials.gov and search "hypophosphatemic rickets" to view active, recruiting studies.
- Connect with the 3 members of the DiseaseMaps.org community who have experience with Rickets to share insights and support.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Rickets
- Orphanet: Rare endocrine diseases database
- OMIM (Online Mendelian Inheritance in Man): Hypophosphatemic Rickets
- The MAGIC Foundation: Educational resources for endocrine disorders
